Related references
Note: Only part of the references are listed.Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor thymidylate synthase 1494de16 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment
E Dotor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients
E Goekkurt et al.
BRITISH JOURNAL OF CANCER (2006)
Polymorphism in the 3 '-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy
JW Lu et al.
JOURNAL OF HUMAN GENETICS (2006)
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers
M Morganti et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
F Lordick et al.
BRITISH JOURNAL OF CANCER (2005)
Cytotoxic effects of pemetrexed in gastric cancer cells
JH Kim et al.
CANCER SCIENCE (2005)
Prognostic role of Thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
K Kawakami et al.
CLINICAL CANCER RESEARCH (2005)
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
F De Vita et al.
BRITISH JOURNAL OF CANCER (2005)
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
A Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
R Suk et al.
CLINICAL CANCER RESEARCH (2005)
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer
SE Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene
K Uchida et al.
CLINICAL CANCER RESEARCH (2004)
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
Y Chao et al.
BRITISH JOURNAL OF CANCER (2004)
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
W Zhou et al.
CLINICAL CANCER RESEARCH (2004)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
S Gurubhagavatula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Palliative chemotherapy for advanced gastric cancer
SS Wöhrer et al.
ANNALS OF ONCOLOGY (2004)
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer
W Ichikawa et al.
BRITISH JOURNAL OF CANCER (2004)
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels
MV Mandola et al.
PHARMACOGENETICS (2004)
Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer
R Mort et al.
BRITISH JOURNAL OF CANCER (2003)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy:: Phenotypic and genotypic analyses
MC Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Polymorphisms of the DNA repair gene XPD:: correlations with risk of basal cell carcinoma revisited
U Vogel et al.
CARCINOGENESIS (2001)
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
KH Yeh et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
